CA-ARMIS
22.1.2024 14:01:31 CET | Business Wire | Press release
Armis, the asset intelligence cybersecurity company, today announced The Anatomy of Cybersecurity: A Dissection of 2023's Attack Landscape. The 2023 analysis of Armis’ proprietary data offers critical insight into the multifaceted challenges global organizations face when it comes to protecting the entire attack surface. Report findings serve as a blueprint to help security teams worldwide prioritize efforts to reduce cyber risk exposure in 2024.
The report found that global attack attempts more than doubled in 2023, increasing 104%. Utilities (over 200% increase) and Manufacturing (165% increase) were the most at risk industries. Attack attempts peaked in July, with communications devices, imaging devices and manufacturing devices experiencing intensified targeting during this period.
“Armis found that not only are attack attempts increasing, but cybersecurity blind spots and critical vulnerabilities are worsening, painting prime targets for malicious actors,” said Nadir Izrael, CTO and Co-Founder, Armis. “It’s critical that security teams leverage similar intelligence defensively so that they know where to prioritize efforts and fill these gaps to mitigate risk. We hope that by sharing these insights, global businesses and governments will leverage them to immediately pinpoint what they should be focusing on to improve their cybersecurity posture this year to keep critical infrastructure, economies and society safe and secure.”
Key findings of The Anatomy of Cybersecurity: A Dissection of 2023's Attack Landscape include:
Geopolitical tensions exacerbate the cybersecurity landscape
-
Cyberwarfare grew more widespread in 2023. Top industries exposed to attack from Chinese and Russian actors were those within Manufacturing, Educational Services and Public Administration.
- In manufacturing, .cn and .ru domains contributed to an average of 30% of monthly attack attempts, while attacks from these domains on Educational Services have risen to about 10% of total attacks.
Legacy technology steepens incline of cybersecurity pros’ existing up-hill battle
-
Older Windows server OS versions (2012 and earlier) are 77% more likely to experience attack attempts compared to newer Windows Server versions.
- This vulnerability is particularly evident in the server environment, with nearly a quarter of server versions facing end-of-support (EoS) scenarios. The Educational Services industry has a significantly higher percentage of servers (41%) with unpatched weaponized Common Vulnerabilities and Exposures (CVEs), compared to the general average of 10%.
- Industries still using end-of-life (EoL) or EoS OSs that are no longer actively supported or patched for vulnerabilities and security issues by the manufacturer: Educational Services (18%), Retail (14%), Healthcare (12%), Manufacturing (11%) and Public Administration (10%).
Businesses struggle with effective vulnerability prioritization and remediation
- There were over 65,000 unique CVEs discovered in 2023.
- Wearable devices have the highest percentage (93%) of unpatched CVEs.
- A third of all devices are still not patched for Log4Shell.
-
Patch rates for critical CVEs are not prioritized:
- Low CVEs: 11% patch rate
- Medium CVEs: 58% patch rate
- High CVEs: 64% patch rate
- Critical CVEs: 55% patch rate
- Irrespective of the weaponization status of a CVE, organizations consistently grapple with patch rates at 62% for non-weaponized and 61% for weaponized vulnerabilities.
“Blueprints like this report are invaluable as they help teams focus limited resources on efforts with the greatest impact and with the insights to tell data-driven stories in justification of cross-team priorities,” said Curtis Simpson, CISO, Armis. “Using hindsight and analyzed data could allow CISOs to focus 2024 efforts on segmenting legacy technology, prioritizing exposures of greatest significance, and utilizing AI-driven technologies that can assist security teams with defending and managing the attack surface in real-time.”
Proprietary data leveraged for this report was mined from Armis’ Asset Intelligence Engine. The Armis Asset Intelligence Engine is a collective AI-powered knowledge base, monitoring billions of assets worldwide, in order to identify cyber risk patterns and behaviors. It feeds the Armis Centrix™ platform with unique, actionable cyber intelligence to detect and address real-time threats across the entire attack surface.
To read the full report, The Anatomy of Cybersecurity: A Dissection of 2023's Attack Landscape, please visit: https://www.armis.com/anatomy-of-cybersecurity
Learn more about The Armis Asset Intelligence Engine here: https://www.armis.com/platform/armis-asset-intelligence-engine/
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122998889/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
